Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 454 | 59 | 395 |
| Samples | 179 | 29 | 150 |
| Peptides | 156 | 21 | 137 |
Function
IL2RA · Interleukin 2 receptor subunit alpha
The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis. Alternately-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown. Mutations in this gene are associated with interleukin 2 receptor alpha deficiency. Patients with severe Coronavirus Disease 2019 (COVID-19), the disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have significantly elevated levels of IL2R in their plasma. Similarly, serum IL-2R levels are found to be elevated in patients with different types of carcinomas. Certain IL2RA and IL2RB gene polymorphisms have been associated with lung cancer risk. [provided by RefSeq, Jul 2020].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 125 amino-acid changes on canonical ENST00000379959 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IL2RA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IL2RA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Melanoma | 0/210 0% | 33/1899 2% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Endometrial Carcinoma | 0/42 0% | 9/612 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 8/1390 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Other Solid Cancers | 0/94 0% | 12/1515 1% |
| Colorectal Carcinoma | 4/143 3% | 15/3239 0% |
| Gastric Carcinoma | 0/74 0% | 10/1809 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 11/2550 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 3/810 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Non-Cancerous | 1/104 1% | 3/830 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Other Sarcomas | 2/69 3% | 1/699 0% |
| Head and Neck Carcinoma | 1/85 1% | 5/1574 0% |
| Hepatocellular Carcinoma | 2/46 4% | 3/2210 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
| Breast Carcinoma | 0/144 0% | 6/3264 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Pancreatic Carcinoma | 1/89 1% | 1/1611 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 2/2534 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
Mutation Distribution
Where IL2RA is mutated · all tissues, split by cell line vs tissue
How many mutations in IL2RA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 46 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 454 mutations in IL2RA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|